Literature DB >> 25974186

Outcomes Associated With Concurrent Iris-Sutured Intraocular Lens Placement and Subluxated Crystalline Lens Extraction.

Scott F McClellan1, Uri Soiberman1, Peter L Gehlbach2, Peter N Murakami3, Walter J Stark1.   

Abstract

IMPORTANCE: We have developed a novel surgical technique, to our knowledge, for the management of subluxated crystalline lenses involving preplacement of an iris-sutured posterior chamber intraocular lens (PCIOL) before pars plana vitrectomy and lensectomy.
OBJECTIVE: To investigate the outcomes of eyes with subluxated crystalline lenses, predominantly a result of Marfan syndrome (14 eyes [58%]) or trauma (5 eyes [21%]), that underwent pars plana vitrectomy and lensectomy with placement of an iris-sutured PCIOL. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective, noncomparative case series of 24 eyes from 17 consecutive adult patients with surgically treated subluxated crystalline lenses presenting to the Wilmer Eye Institute at Johns Hopkins Hospital from October 6, 2006, through May 1, 2013. The mean (SD) postoperative follow-up was 24.4 (20.5) months for eyes with at least 6 months of follow-up (last date, October 13, 2014). We performed the analysis from January 21, 2014, through January 3, 2015. MAIN OUTCOMES AND MEASURES: Improvement in best-corrected visual acuity using an automated Snellen chart and induction of astigmatism for eyes with at least 6 months of follow-up (n = 18) and IOL stability during follow-up for all eyes (n = 24).
RESULTS: The mean (SD) age at surgery was 49.4 (10.7 [range, 29-67]) years. We found an improvement in mean (SD [95% CI]) best-corrected visual acuity from 0.66 (0.71 [0.30-1.02]) logMAR preoperatively (Snellen equivalent, approximately 20/90; range, 20/30 to hand motions) to 0.07 (0.11 [95% CI, 0.01-0.12]) logMAR postoperatively (Snellen equivalent, approximately 20/23; range, 20/15 to 20/50). We found little change in astigmatism postoperatively (mean change, -0.1 [95% CI, -0.5 to 0.13] diopters). Postoperative complications included retinal detachment (1 eye [4%]), retained cortical fragment (1 [4%]), cystoid macular edema (2 [8%]), and IOL subluxation (3 [13%]) owing to haptic slippage within 3 months of the procedure. The overall probability of successfully achieving placement of a centered iris-sutured PCIOL in patients with follow-up of longer than 6 months (n = 18) was 100% (95% CI, 81.5%-100%). CONCLUSIONS AND RELEVANCE: Placement of iris-sutured PCIOLs at the time of subluxated lens extraction with a pars plana surgical approach yields favorable results in terms of postoperative visual outcomes and surgical complications. This technique offers an effective procedure for surgeons to use when treating clinically significant subluxated crystalline lenses.

Entities:  

Mesh:

Year:  2015        PMID: 25974186     DOI: 10.1001/jamaophthalmol.2015.1097

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  4 in total

1.  Surgical outcomes and complications of sutureless needle-guided intrascleral intraocular lens fixation combined with vitrectomy.

Authors:  Komal Shelke; Ekta Rishi; Pukhraj Rishi
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848

2.  1 Year Surgical Outcomes and Safety of Combined Trans Pars Plana Vitrectomy with Iris Fixated Posterior Chamber Intraocular Lens for Subluxated Intraocular Lens and Cataracts.

Authors:  Valencia Hui Xian Foo; Tiffany Sin Hui Bong; Andrew Tsai; Laurence Shen Lim; Shamira Asith Perera
Journal:  Clin Ophthalmol       Date:  2021-10-07

3.  Outcomes of Transscleral Two-Point Fixation Versus Closed Continuous-Loop Four-Point Fixation of Intraocular Lens in Subluxated Lens Secondary to Marfan Syndrome.

Authors:  Xiang Gao; Wenting Zhu; Jingyi Tian; Xiaolei Sun; Ziyi Ni; Gongqiang Yuan; Jingjing Zhang
Journal:  Ophthalmol Ther       Date:  2022-05-20

4.  The Technique of Phacoemulsification and Intraocular Lens Implantation in Subluxated Cataract Surgery.

Authors:  Huaiyan Jiang; Wenzhong Fu; Hongxia Xu
Journal:  Stem Cells Int       Date:  2022-10-06       Impact factor: 5.131

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.